Progressive Multifocal Leucoencephalopathy (PML) Treatment Receives US Orphan Drug Designation

Cytheris SA, a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, has announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for Cytheris' CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML). This designation from the FDA follows orphan drug designation for the same indication granted in Europe in July 2012 from the European Commission... via Health News from Medical News Today Read More Here..